1. SEIKAGAKU CORPORATION
  2. Investors
  3. IR Library
  4. Presentation Material
Presentation Material
サブ-ナビゲーション
  • TOP
  • News Release
  • Who we are
  • ”Hyaluronic Acid” Expedition
  • What is Glycoscience
  • Management Policy
  • Highlights
  • Stock Information
  • Our R&D
  • Sustainability
  • Investors
    • News Release
    • What's New
    • Management Policy
    • Highlights
    • IR Library
      • Summary of Financial Results
      • ->Presentation Material
      • Corporate Report
    • IR Schedule
    • Shareholder Information
    • IR E-mail Alert
  • Our Company
  • Privacy Policy
  • Terms of Use
  • Sitemap

Presentation Material

FY2025

  • Financial Results for the Second Quarter of Fiscal Year 2025 （2,101KB）
  • ┗　Script （3,315KB）
  • ┗　Q&A Summary （288KB）
  • Financial Results for the First Quarter of Fiscal Year 2025 （2,012KB）

FY2024

  • Financial Results for the Fiscal Year 2024 （1,865KB）
  • Financial Results for the Third Quarter of Fiscal Year 2024 （1,797KB）
  • Financial Results for the Second Quarter of Fiscal Year 2024 （1,886KB）
  • Financial Results for the First Quarter of Fiscal Year 2024 （1,829KB）

FY2023

  • Financial Results for the Fiscal Year 2023 （1,895KB）
  • Financial Results for the Third Quarter of Fiscal Year 2023 （1,177KB）
  • Financial Results for the Second Quarter of Fiscal Year 2023 （1,432KB）
  • Financial Results for the First Quarter of Fiscal Year 2023 （3,690KB）

FY2022

  • Financial Results for the Fiscal Year 2022 （2,627KB）
  • Financial Results for the Third Quarter of Fiscal Year 2022 （2,664KB）
  • Financial Results for the Second Quarter of Fiscal Year 2022 （2,756KB）
  • Financial Results for the First Quarter of Fiscal Year 2022 （2,728KB）

FY2021

  • Financial Results for the Fiscal Year 2021 （2,787KB）
  • Financial Results for the Third Quarter of Fiscal Year 2021 （2,637KB）
  • Financial Results for the Second Quarter of Fiscal Year 2021 （2,671KB）
  • Financial Results for the First Quarter of Fiscal Year 2021 （2,724KB）

FY2020

  • Financial Results for the Fiscal Year 2020 （2,750KB）
  • Financial Results for the Third Quarter of Fiscal Year 2020 （2,456KB）
  • Financial Results for the Second Quarter of Fiscal Year 2020 （3,359KB）
  • Financial Results for the First Quarter of Fiscal Year 2020 （2,532KB）

FY2019

  • Financial Results for the Fiscal Year 2019 （2,352KB）
  • Financial Results for the Third Quarter of Fiscal Year 2019 （2,701KB）
  • Financial Results for the Second Quarter of Fiscal Year 2019 （3,113KB）
  • Financial Results for the First Quarter of Fiscal Year 2019 （2,993KB）

FY2018

  • Financial Results for the Fiscal Year 2018 （3,092KB）
  • Financial Results for the Third Quarter of Fiscal Year 2018 （1,988KB）
  • Financial Results for the Second Quarter of Fiscal Year 2018 （2,002KB）
  • Financial Results for the First Quarter of Fiscal Year 2018 （1,834KB）

FY2017

  • Financial Results for the Fiscal Year 2017 （1,563KB）
  • Financial Results for the Second Quarter of Fiscal Year 2017 （1,663KB）

FY2016

  • Financial Results for the Fiscal Year 2016 （1,443KB）
  • Financial Results for the Second Quarter of Fiscal Year 2016 （1,673KB）

FY2015

  • Financial Results for the Fiscal Year 2015 （1,935KB）
  • Financial Results for the Second Quarter of Fiscal Year 2015 （1,430KB）

FY2014

  • Financial Results for the Fiscal Year 2014 （1,438KB）
  • Financial Results for the Second Quarter of Fiscal Year 2014 （1,391KB）

FY2013

  • Financial Results for the Fiscal Year 2013 （2,110KB）
  • Financial Results for the Second Quarter of Fiscal Year 2013 （3,130KB）

FY2012

  • Financial Results for the Fiscal Year 2012 （1,275KB）
  • Financial Results for the Second Quarter of Fiscal Year 2012 （1,170KB）

FY2011

  • Financial Results for the Fiscal Year 2011 （1,039KB）
  • Financial Results for the Second Quarter of Fiscal Year 2011 （668KB）

FY2010

  • Financial Results for the Fiscal Year 2010 （699KB）
  • Financial Results for the Second Quarter of Fiscal Year 2010 （2,131KB）

FY2009

  • Financial Results for the Fiscal Year 2009 （1,813KB）
  • Financial Results for the Second Quarter of Fiscal Year 2009 （777KB）

This link will direct you to a third-party site.（Another window opens.）

Please click here

Step back to the Seikagaku Corporation website

The Seikagaku Corporation website uses cookies to personalize contents and offer a better browsing experience. Please click the Accept botton. （Read more）

Accept

生化学工業株式会社
  • 日本語
  • ”Hyaluronic Acid” Expedition
  • Contact Us　

Who we are

What is Glycoscience

What is Glycoscience

Are glucides sweet?

Glycoscience in one minute

Introduction to the Glycoscience

Glycoscience in one minute

Glycoscience in one minute

”Hyaluronic Acid” Expedition

”Hyaluronic Acid” Expedition

Our R&D

Our R&D

R&D Basic Policy

R&D Structure

R&D Pipeline

Process of new drug development

Intellectual Property

R&D Basic Policy

R&D Basic Policy

R&D Pipeline

R&D Pipeline

Sustainability

Sustainability

Sustainability Management

Materiality

Stakeholder Engagement

Environmental Policy

Environmental Impact Reduction Initiatives

Initiatives for Biodiversity

Information Disclosure Based on
the TCFD Recommendations

Social Contribution Activities

Human Resource Development

Diversity and Work-Life Balance

Corporate Governance

Compliance

Risk Management

Our Policy

ESG Data Book

External Evaluations

Materiality

Materiality

Investors

Investors

News Release

What's New

Management Policy

Highlights

IR Library

IR Schedule

Shareholder Information

IR E-mail Alert

Message from President & CEO

Message from President & CEO

Our Company

Our Company

Greeting

Corporate Philosophy

History

Corporate Profile

Member of the Board

Organizational Chart

Corporate Governance

Compliance

Value Creation Process

Social Contribution Activities

Business Activities

Corporate Philosophy

Corporate Philosophy

Business Activities

Business Activities
生化学工業株式会社

Who we are

What is Glycoscience

Are glucides sweet?

Glycoscience in one minute

Introduction to the Glycoscience

  • Part 1　Invitation to Glycoscience
  • Part 2　Fertilization
  • Part 3　Source of Energy
  • Part 4　Extracellular matrix 1
  • Part 5　Extracellular matrix 2
  • Part 6　Cell proliferation and differentiation
  • Part 7　Blood type
  • Part 8　Cancer
  • Part 9　Viral infection
  • Part 10　Applications and Developments

”Hyaluronic Acid” Expedition

Hyaluronic Acid - I am also in your home

Hyaluronic Acid- Everywhere in your body

Hyaluronic Acid- This is what I am!

Hyaluronic Acid- How I work in your body

Story Time

Our R&D

R&D Basic Policy

R&D Structure

R&D Pipeline

Process of new drug development

Intellectual Property

Sustainability

Sustainability Management

Materiality

Stakeholder Engagement

Environmental Policy

Environmental Impact Reduction Initiatives

Initiatives for Biodiversity

Information Disclosure Based on
the TCFD Recommendations

Social Contribution Activities

Human Resource Development

Diversity and Work-Life Balance

Corporate Governance

Compliance

Risk Management

Our Policy

ESG Data Book

External Evaluations

Investors

News Release

What's New

Management Policy

  • Message from President & CEO
  • Mid-term Management Plan
  • R&D Pipeline
  • Profit Distribution Policies
  • Business Risks

Highlights

  • Business Performance
  • Business Performance（Quarter）
  • Cash Flow
  • Business Performance Data Download

IR Library

  • Summary of Financial Results
  • Presentation Material
  • Corporate Report

IR Schedule

Shareholder Information

  • Stock Information
  • Shareholder Composition
  • Profit Distribution
  • General Meeting of Shareholders
  • Analyst Coverage
  • Stock Price

IR E-mail Alert

Our Company

Greeting

Corporate Philosophy

History

Corporate Profile

Member of the Board

Organizational Chart

Corporate Governance

Compliance

Value Creation Process

Social Contribution Activities

Business Activities

  • Business Segment
  • Products
    • Pharmaceuticals and Medical Devices
    • Bulk Products
      • Sodium Hyaluronate
      • Sodium Chondroitin Sulfate
    • LAL Business
    • Contract development and manufacturing organization (CDMO)
  • Production
  • Quality Compliance
  • Contact Us
  • 日本語
To page top
To page top

Who we are

What is Glycoscience

Are glucides sweet?

Glycoscience in one minute

Introduction to the Glycoscience

”Hyaluronic Acid” Expedition

Hyaluronic Acid - I am also in your home

Hyaluronic Acid- Everywhere in your body

Hyaluronic Acid- This is what I am!

Hyaluronic Acid- How I work in your body

Story Time

Our R&D

R&D Basic Policy

R&D Structure

R&D Pipeline

Process of new drug development

Intellectual Property

Sustainability

Sustainability Management

Materiality

Stakeholder Engagement

Environmental Policy

Environmental Impact Reduction Initiatives

Initiatives for Biodiversity

Information Disclosure Based on
the TCFD Recommendations

Social Contribution Activities

Human Resource Development

Diversity and Work-Life Balance

Corporate Governance

Compliance

Risk Management

Our Policy

ESG Data Book

External Evaluations

Investors

News Release

What's New

Management Policy

Highlights

IR Library

IR Schedule

Shareholder Information

IR E-mail Alert

Our Company

Greeting

Corporate Philosophy

History

Corporate Profile

Member of the Board

Organizational Chart

Corporate Governance

Compliance

Value Creation Process

Social Contribution Activities

Business Activities

Copyright © SEIKAGAKU CORPORATION All rights Reserved.

  • Privacy Policy
  • Terms of Use